Who is sponsoring NCT00089193?

NCT00089193 is sponsored by Craig L Slingluff, Jr.

What condition does NCT00089193 study?

NCT00089193 studies Melanoma (Skin).

What drugs are being tested in NCT00089193?

Interventions: incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim.

What is the status of NCT00089193?

NCT00089193 is currently COMPLETED.

Last reviewed 2014-12-18 · How we verify

Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides

NCT00089193 Phase 2 COMPLETED

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a stronger immune response and kill more tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients with stage II B, stage IIC, stage III, or stage IV melanoma.

Details

Lead sponsor	Craig L Slingluff, Jr
Phase	Phase 2
Status	COMPLETED
Start date	2003-09

Conditions

Melanoma (Skin)

Interventions

incomplete Freund's adjuvant
multi-epitope melanoma peptide vaccine
sargramostim

Countries

United States